Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

Acta Neurologica Scandinavica
D NilssonS M Aquilonius

Abstract

To evaluate the effects of continuous duodenal infusion of levodopa over time on the disabling fluctuations in motor performance in advanced parkinsonian patients. It has earlier been demonstrated that these fluctuations can be reduced by keeping the plasma concentration of levodopa constant. In view of the low water solubility of levodopa a stable dispersion of the drug was developed and used for continuous intraduodenal infusion in patients with advanced Parkinson's disease. Nine patients were evaluated with respect to an optimal oral treatment, during nasoduodenal infusion by a portable pump and then followed for 6 months to 2 1/2 years when treated via transabdominal infusion. Upon each test occasion, over 2 non-consecutive days, objective movement analysis by means of an opto-electronic system was applied every 15-20 min and video recordings performed twice every h. On several test occasions plasma levodopa concentrations were analysed every 15 min. The patients showed improvement and decreased variance of their motor function. In the 2 patients followed over a period of 2 1/2 years levodopa plasma concentration showed reduced fluctuations on infusion and the levodopa consumption as well as mean levodopa plasma concentrati...Continue Reading

References

Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·G StegM Thorselius
Jul 1, 1988·Annals of Neurology·J I SageR C Duvoisin
Apr 1, 1986·Annals of Neurology·C H Markham, S G Diamond
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·U K Rinne
Feb 23, 1984·The New England Journal of Medicine·J G NuttJ L Anderson
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·B JohnelsG Steg
Mar 1, 1993·British Journal of Clinical Pharmacology·H LennernäsL K Paalzow
Oct 1, 1995·Clinical Pharmacokinetics·S HarderS Rietbrock

❮ Previous
Next ❯

Citations

Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi
Aug 9, 2006·Expert Review of Neurotherapeutics·Alan Diamond, Joseph Jankovic
Sep 20, 2008·Journal of Neurology·Heinz Reichmann
Nov 1, 2002·Expert Review of Neurotherapeutics·Fabrizio Stocchi
Jan 31, 2014·Journal of Neurology·María T Cáceres-RedondoPablo Mir
May 15, 2015·Translational Neurodegeneration·Fabrizio StocchiFabiana G Radicati
Feb 24, 2016·Current Neurology and Neuroscience Reports·Yasaman Kianirad, Tanya Simuni
Dec 17, 2004·Clinical Neuropharmacology·Dag Nyholm, Sten-Magnus Aquilonius
Mar 1, 2011·Current Medical Research and Opinion·H H Fernandez, P Odin
Feb 15, 2011·Expert Opinion on Drug Delivery·Shadab MdJaved Ali
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Fabrizio StocchiC Warren Olanow
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Fabrizio Stocchi
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Johan Samanta, Robert A Hauser
Mar 3, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·David Devos, UNKNOWN French DUODOPA Study Group
Jun 19, 2015·Acta neurologica Belgica·F BellanteD Zegers de Beyl
May 1, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowUNKNOWN Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators
Mar 21, 2002·Acta Neurologica Scandinavica·D NilssonS M Aquilonius
Oct 18, 2005·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Anthony E LangOksana Suchowersky
Nov 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M Steiger
Apr 3, 2008·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Apr 6, 2016·Neurology·Peter A LeWitt, Stanley Fahn
Apr 15, 2016·Neurodegenerative Disease Management·Diego Santos GarcíaNatividad Mariscal Pérez
Jun 5, 2003·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues
Oct 6, 2009·Applied Health Economics and Health Policy·Ivar Sønbø KristiansenDag Isacson
Mar 10, 2017·Upsala Journal of Medical Sciences·Sten-Magnus Aquilonius, Dag Nyholm
Aug 21, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowJose A Obeso
Apr 4, 2021·Journal of Personalized Medicine·Mezin ÖthmanDag Nyholm
May 26, 2004·International Journal of Pharmaceutics·Amnon HoffmanMichael Friedman
Jan 30, 2007·Progress in Neurobiology·Neha SinghYahya E Choonara

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.